Orexin B Research: What Published Studies Have Investigated

What is orexin B?

What is orexin B? A 28-residue neuropeptide, also called hypocretin-2, cut from residues 70–97 of the 131-residue prepro-orexin precursor (UniProt O43612). The same precursor yields orexin A from residues 34–66. Both were reported in 1998 by two groups working independently — de Lecea and colleagues in PNAS, who named the family the hypocretins, and Sakurai and colleagues in Cell, who named it the orexins. That story, and the reason both names persist, is set out on the orexin A page rather than repeated here.

What is worth saying immediately is that “same precursor” does not mean “near-identical peptide”. The two mature products share a C-terminal region — both terminate in the identical nine-residue stretch GNHAAGILT, differing only in the single final residue — leucine in orexin A, methionine in orexin B — and diverge substantially at the N-terminal end. Orexin B has no cysteines at all, where orexin A has four. In practical terms they are as different as two peptides from one precursor can be.

Structure: linear, two-helix, and easier to make

The NMR picture

Lee and colleagues determined the solution structure of human hypocretin-2/orexin-B by two-dimensional ¹H-NMR with dynamical simulated annealing, reporting it in the European Journal of Biochemistry in 1999 (PMID 10583376). From NOEs, ³J_HNα coupling constants, hydrogen–deuterium exchange rates and chemical-shift indices, they described the peptide as two alpha-helices connected by a short linker, with helix I oriented roughly 60–80 degrees to helix II, in both water and 30% trifluoroethanol. They generated an ensemble of thirty structures with no constraint violations above 0.03 nm for distances, and noted that the resulting fold shares a secondary-structural motif with human neuropeptide Y.

Miskolzie, Lucyk and Kotovych (2003, J Biomol Struct Dyn, PMID 14616030) subsequently examined orexin-B bound to micelles — a membrane-mimetic environment rather than free solution — which is the standard follow-up question for a peptide expected to approach a receptor at a membrane surface.

The comparison that defines it

Kim and colleagues (2004, PMID 15479620), determining the orexin A structure, made the comparison explicit: orexin A also folds into two helices with amphipathic character, and what distinguishes the two peptides is a hydrophilic turn imposed by orexin A’s two disulfide bonds — a constraint orexin B simply does not have. Orexin B is the conformationally freer of the pair.

That freedom has a practical corollary for anyone sourcing the peptide, and it is a rare case where the simpler molecule is the more trustworthy product: a linear peptide with no cysteines has no disulfide-pairing problem, so a mass and a purity figure describe it far more completely than they describe its sibling.

Reference data

From the reviewed UniProt record for the human precursor (O43612) and the public chemical record (PubChem CID 44404987).

The single sulfur atom in that formula is the C-terminal methionine, not a cysteine — a useful cross-check against orexin A’s four sulfurs. No reconstitution procedure, quantity or route is given or implied on this page.

Receptor selectivity, and how much to trust the numbers

This is the mechanistically important part of the page, and it needs to be stated carefully because it is the point most often overstated elsewhere.

The IUPHAR/BPS Guide to Pharmacology curates agonist potency data for both peptides at both receptors, drawing on more than a dozen studies each. At OX₂R, the published pEC₅₀ ranges for orexin A and orexin B overlap almost completely. At OX₁R, the curated range for orexin B sits below the range for orexin A. That asymmetry is the whole of the selectivity story: orexin A is the non-selective ligand; orexin B is the one that prefers OX₂R — and it prefers it modestly, not absolutely.

The honest qualifier belongs alongside that: the curated ranges are wide — spanning several log units at each receptor, across assay formats, cell backgrounds and readouts. Secondary sources routinely quote a single tidy affinity figure for each peptide at each receptor. Those figures come from one study among many, and the spread in the aggregated data is the more accurate description of what is known.

• Why the modest selectivity mattered enough to fix. Because orexin B is not selective enough to isolate OX₂R signalling experimentally, the field built an analogue. [Ala¹¹, D-Leu¹⁵]orexin-B is curated in the same database as an agonist with reported potency at OX₂R above its potency at OX₁R, and it is the standard tool when a study needs OX₂R activation cleanly. Its existence is the clearest evidence of where the parent peptide falls short.
• Shared downstream signalling. Both receptors were deorphanised together in the Sakurai 1998 paper, and nothing in this literature suggests orexin B activates a pathway orexin A does not. The difference between the two peptides is which receptor they engage, not what happens after it is engaged.

Research findings by area

The dog result: why OX2R is the interesting receptor

Lin and colleagues reported in Cell in August 1999 (PMID 10458611) that canine narcolepsy — a naturally occurring, inherited sleep disorder in dogs, studied for decades before anyone knew its cause — is produced by a mutation in the hypocretin (orexin) receptor 2 gene. This is a loss-of-function experiment nature ran on its own, in a large mammal, with a clean phenotype, and it points at a single receptor.

Chemelli and colleagues reported in the same journal two weeks later (PMID 10481909) that mice lacking the orexin peptides show a narcolepsy phenotype including cataplexy. The two results converge: knock out the ligands, or knock out one receptor, and the same disorder results. That is why OX₂R, and by extension the peptide that prefers it, occupies the position it does in this field.

Where orexin B is actually used

In practice orexin B’s research role is as a comparison ligand and a starting scaffold rather than as the field’s primary reagent. It appears in receptor-pharmacology studies to establish selectivity profiles, in structural work as the tractable linear counterpart to orexin A, and as the backbone from which the OX₂R-selective analogue was derived. The clinical and biomarker literature — CSF measurement, post-mortem peptide and neuron counts in human narcolepsy — is orexin A’s, and is covered on that page.

What the field built instead

As with orexin A, the drugs that reached approval in this system are small-molecule receptor antagonists for insomnia, not peptides. A reader encountering the large post-2010 orexin literature should note that most of it concerns blocking these receptors, and none of it transfers to statements about administering either peptide.

Research models and evidence status

What is solid

The peptide’s sequence, precursor origin, terminal amidation and absence of disulfides are settled facts with a reviewed protein-database record behind them. Its solution structure has been determined by NMR in two environments by two groups. Its receptor pharmacology is characterised across many laboratories and independently curated. The genetic link between OX₂R and narcolepsy in dogs is a landmark result that has not been challenged.

What is not established

Everything about administering the peptide. There is no published human pharmacokinetic, safety or tolerability dataset for orexin B that we could locate, and no clinical trial of the peptide as an administered compound. The evidence in this system is about receptor genetics, structural biology, and small-molecule antagonism — none of which is evidence about giving a peptide to anyone.

Two further honest limits. First, the selectivity difference between the two peptides is real but modest, and is frequently exaggerated in secondary material into a clean OX₁/OX₂ division that the curated data do not support. Second, orexin B has no biomarker or clinical literature of its own; the human findings in this field concern its sibling, and a claim that borrows them for orexin B is borrowing from a different molecule.

Nothing in this literature establishes any property of the supplied research material in a person. This page makes no efficacy, therapeutic, wakefulness, appetite or other use claim of any kind, and the material is supplied for laboratory research use only — not for human or veterinary use.

How to verify this compound yourself

Orexin B is, unusually, the easier of the two siblings to certify — and the reason is worth stating because it flips the normal assumption that the more elaborate molecule is the better-documented one:

• Mass-spec identity is close to decisive here. With no cysteines there is no disulfide-pairing ambiguity: a single molecular species of roughly 2899 Da, correctly amidated, is the molecule. Compare that with orexin A, where three different disulfide pairings share one mass and a routine certificate cannot tell them apart.
• The mass gap between the siblings is enormous. Roughly 2899 Da against roughly 3561 Da — more than 600 Da. A mislabelled vial is not a subtle analytical problem; it is visible on the first line of the mass-spec report.
• C-terminal amidation is a genuine variable. The peptide is a methionine amide. An unamidated free-acid version differs by 1 Da, which is resolvable by high-resolution mass spectrometry but not by a nominal-mass measurement — so it is worth knowing what resolution the certificate’s instrument reports.
• The methionine can oxidise. Methionine sulfoxide is 16 Da heavier and forms on storage and handling, particularly in solution and in light. A shoulder or satellite peak 16 Da above the expected mass is the signature, and it is a stability question rather than a synthesis failure.
• HPLC purity on a 28-mer carries real information — at this length deletion sequences accumulate, so the percentage means something, unlike on a very short peptide where a high figure is nearly automatic.

See how to read a COA for what each certificate line means, and how to verify peptide purity for how the methods fit together. The exact batch received can be checked on the self-serve verify tool.

Research-grade sourcing and verification

Orexin B is not held in stock. It is listed on our sourcing catalogue as available to order — our supplier lists it, we have not bought it, and material of this kind typically takes about two to three weeks to reach us. For laboratory research use only, it is supplied with a per-batch Certificate of Analysis reporting HPLC purity (%) and mass-spec identity confirmation, verifiable at the lot level. Its sibling peptide has its own page: orexin A research, which also carries the shared 1998 discovery history. For other endogenous peptides in this library studied in sleep and circadian contexts, see DSIP research and melatonin research. This is sourcing and quality-assurance framing only.

Frequently asked questions

Literature cited

1. Sakurai T, Amemiya A, Ishii M, et al. “Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior.” Cell. 1998;92(4):573–585. PMID 9491897. pubmed.ncbi.nlm.nih.gov/9491897.
2. Lin L, Faraco J, Li R, et al. “The sleep disorder canine narcolepsy is caused by a mutation in the hypocretin (orexin) receptor 2 gene.” Cell. 1999;98(3):365–376. PMID 10458611. pubmed.ncbi.nlm.nih.gov/10458611. The OX₂R result.
3. Chemelli RM, Willie JT, Sinton CM, et al. “Narcolepsy in orexin knockout mice: molecular genetics of sleep regulation.” Cell. 1999;98(4):437–451. PMID 10481909. pubmed.ncbi.nlm.nih.gov/10481909.
4. Lee JH, Bang E, Chae KJ, Kim JY, Lee DW, Lee W. “Solution structure of a new hypothalamic neuropeptide, human hypocretin-2/orexin-B.” Eur J Biochem. 1999;266(3):831–839. PMID 10583376. pubmed.ncbi.nlm.nih.gov/10583376. The two-helix solution structure.
5. Miskolzie M, Lucyk S, Kotovych G. “NMR conformational studies of micelle-bound orexin-B: a neuropeptide involved in the sleep/awake cycle and feeding regulation.” J Biomol Struct Dyn. 2003;21(3):341–351. PMID 14616030. pubmed.ncbi.nlm.nih.gov/14616030.
6. Kim HY, Hong E, Kim JI, Lee W. “Solution structure of human orexin-A: regulator of appetite and wakefulness.” J Biochem Mol Biol. 2004;37(5):565–573. PMID 15479620. pubmed.ncbi.nlm.nih.gov/15479620 (the disulfide-turn comparison between the two peptides).
7. UniProt Consortium. “O43612 — Hypocretin neuropeptide precursor (human).” uniprot.org/uniprotkb/O43612 (precursor length, peptide boundaries, C-terminal amidation, absence of disulfides in orexin B).
8. National Center for Biotechnology Information. “PubChem Compound Summary for CID 44404987, Orexin-B.” pubchem.ncbi.nlm.nih.gov/compound/44404987 (formula, mass, CAS 205599-76-4).
9. Harding SD, Armstrong JF, Faccenda E, et al. “Orexin receptors.” IUPHAR/BPS Guide to Pharmacology. guidetopharmacology.org (curated agonist potency ranges for orexin A, orexin B and [Ala¹¹, D-Leu¹⁵]orexin-B at both receptors).